Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Journal of Preventive Medicine ; (12): 1208-1213, 2016.
Artículo en Chino | WPRIM | ID: wpr-792569

RESUMEN

Objective To evaluate vaccine efficacy(VE)of Haemophilus influenza type b vaccine (Hib)among children under five years of age .Methods Searching “National Center for Biotechnology Information,NCBI”,“Cochrane Library, CL”,“China Biology Medicine disc,CBMd”,“China National Knowledge Infrastructure,CNKI”,“Wanfang Database, the studies of VE for Hib among children under five years of age were included,and meta -analysis were made by RevMan 5.3 software.Results A total of 9 studies were included,seven were randomised clinical trial(RCT)design and two were semi RCT design.The VEs of one dose,two doses and three doses of Hib were 65%(95%CI:23% -84%),79%(95%CI:54% -90%),and 85%(95%CI:77% -90%),respectively.Conclusion We found that Hib is highly effective and that the two dose regime is as good as the three dose regime.

2.
Journal of Korean Medical Science ; : 90-96, 2010.
Artículo en Inglés | WPRIM | ID: wpr-64136

RESUMEN

A meta-analysis was performed on the immunogenicity of Haemophilus influenzae type b (Hib) conjugate vaccines after 2 (2 and 4 months) and 3 doses (2, 4, and 6 months) in Korean infants. A database search of MEDLINE, KoreaMed, and Korean Medical Database was done. The primary outcome measure was the proportion of infants with anti-polyribosylribitol phosphate (PRP) concentrations > or =1.0 microgram/mL. Eight studies including eleven trials were retrieved. One trial reported on the diphtheria toxoid conjugate vaccine (PRP-D) and 2 trials each on the mutant diphtheria toxin (PRP-CRM) and Neisseria meningitidis outer-membrane protein (PRP-OMP) conjugate vaccine. Heterogeneity in study designs between trials on PRP-CRM was noted and one trial reported on a monovalent and another on a combination PRP-OMP vaccine. Thus, a meta-analysis was conducted only on the tetanus toxoid conjugate vaccine (PRP-T). After a primary series of 2 doses and 3 doses, 80.6% (95% confidence interval [CI]; 76.0-85.1%) and 95.7% (95% CI; 94.0-98.0%) of infants achieved an antibody level > or =1.0 microgram/mL, respectively. The immunogenic response to the PRP-T vaccine was acceptable after a primary series of 3 doses and also 2 doses. A reduced number of doses as a primary series could be carefully considered in Korean infants.


Asunto(s)
Humanos , Lactante , Anticuerpos/análisis , Cápsulas Bacterianas/inmunología , Vacunas contra Haemophilus/inmunología , República de Corea , Toxoide Tetánico/química , Vacunas Conjugadas/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA